More than 20 years after receiving hematopoietic stem cell transplants for the treatment of beta-thalassemia, 109 patients' long-term health-related quality of life was comparable to that of the general population. Based on responses to the Medical Outcomes Study 36-Item Short-Form Health Survey and the Functional Assessment of Cancer Therapy–Bone Marrow Transplant, patients had better quality-of-life profiles after stem cell transplants than with conventional treatment. Patients who were older at transplant and those who developed graft-versus-host disease had poorer outcomes for general health.

Related Summaries